retatrutide triple hormone receptor agonist obesity Agonist: Mechanism, Evidence, and UK Status – Bolt Pharmacy Mazdutide vs retatrutide: dual agonist

Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al

Protocol 2: the tirzepatide micro-step escalation Goal: Avoid the dramatic side effects common with standard 2.5 mg escalation jumps Schedule (compounded tirzepatide required): Weeks 1-4: 2.5 mg weekly Weeks 5-8: 3.0 mg weekly Weeks 9-12: 3.75 mg weekly Weeks 13-16: 5.0 mg weekly Weeks 17-20: 6.25 mg weekly Weeks 21-24: 7.5 mg weekly Continue escalating by 1.25-2.5 mg every 4 weeks as needed Why the plotter supports this: The standard jump from 2.5 mg to 5 mg produces a transition spike where your first-week peak at 5 mg can exceed the eventual 5 mg steady-state peak by 15-25%

Gluta & GHK-Cu

GLP-1 receptor agonists and the risk for cancer: a meta-analysis of randomized controlled trials